TAG, CRAG, and TB CAB Letter Calling for Compassionate Use Program for Delamanid
TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.
Roadmap for Childhood TB: Towards Zero Deaths
The World Health Organization, the International Union Against Tuberculosis and Lung Disease, the Stop TB Partnership and other partners will launch a roadmap outlining the path towards zero deaths from childhood tuberculosis.
Treatment Action Group and the Stop TB Partnership Issue Update on 2011 Global TB R&D Investment Trends
For the seventh year, Treatment Action Group (TAG) and the Stop TB Partnership have published the latest investment data on the state of global tuberculosis (TB) research and development (R&D) funding.
Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)
May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…
Childhood TB Advocacy Meeting Presentations
On January 5, 2012, TAG held a Childhood TB Federal Advocacy Meeting in Washington, D.C. The meeting was cosponsored by STOP TB, RESULTS/ACTION, the Center for Global Health Policy, and the American Thoracic Society (ATS). Some of the highlights of the…
US Government HIV/AIDS Clinical Trial Sites to Accelerate Completion of Phase III TB Drug Trial
TB Alliance's REMox TB program leverages ACTG sites to advance testing of improved TB treatments November 15, 2011, Durban, South Africa— The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases' (NIAID)…